BufferGel

From Wikipedia, the free encyclopedia

BufferGel is the brand name of a spermicide and microbicide gel which is being tested for its potential development into a preventive medicine to stop the transmission of HIV.

Testing[]

In macaques, after BufferGel's effect on microflora and pH were measured by vaginal colposcopy and rectal lavage researchers determined that it fit the safety profile of a drug which could be tested on humans.[1]

A phase I clinical trial done on women in India, Thailand gave supporting evidence that users tolerate the drug well.[2] A similar trial in the United States also showed drug tolerance.[3]

References[]

  1. ^ Zeitlin, L.; Hoen, T. E.; Achilles, S. L.; Hegarty, T. A.; Jerse, A. E.; Kreider, J. W.; Olmsted, S. S.; Whaley, K. J.; Cone, R. A.; Moench, T. R. (2001). "Tests of Buffergel for contraception and prevention of sexually transmitted diseases in animal models". Sexually Transmitted Diseases. 28 (7): 417–423. doi:10.1097/00007435-200107000-00010. PMID 11460027.
  2. ^ Wijgert, Janneke van de; Andrew Fullem; Clifton Kelly; Sanjay Mehendale; Sungwal Rugpao; Newton Kumwenda; Zvavahera Chirenje; Smita Joshi; Nancy Padian; Robert Bollinger; Kenrad Nelson (2001). "Phase 1 Trial of the Topical Microbicide BufferGel: Safety Results From Four International Sites". Journal of Acquired Immune Deficiency Syndromes. Philadelphia: Lippincott Williams & Wilkins. 26 (1): 21–27. doi:10.1097/00042560-200101010-00003.
  3. ^ Mayer, K. H.; Peipert, J.; Fleming, T.; Fullem, A.; Moench, T.; Cu-Uvin, S.; Bentley, M.; Chesney, M.; Rosenberg, Z. (2001). "Safety and Tolerability of BufferGel, a Novel Vaginal Microbicide, in Women in the United States". Clinical Infectious Diseases. 32 (3): 476–482. doi:10.1086/318496. PMID 11170957.

External links[]

Retrieved from ""